DIAGONAL BIO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0752 SEK | -5.41% |
|
-13.96% | -78.70% |
| 04-05 | Diagonal Bio AB Announces the Extension of Its Partnership with Horsholm Veterinary Clinic | CI |
| 04-05 | Diagonal Bio AB Announces Successful Pilot Study Results | CI |
| Sales 2021 | 8.67M 794K 1.08M | Sales 2022 | 3.71M 339K 463K | Capitalization | 10.06M 921K 1.26M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -1.01M -1.38M | Net income 2022 | -16M -1.46M -2M | EV / Sales 2021 | 7.06 x |
| Net cash position 2021 | 20.77M 1.9M 2.6M | Net cash position 2022 | 13.58M 1.24M 1.7M | EV / Sales 2022 | -0.95 x |
| P/E ratio 2021 |
-5.28
x | P/E ratio 2022 |
-0.65
x | Employees | 4 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.41% | ||
| 1 week | -13.96% | ||
| Current month | -14.74% | ||
| 1 month | -14.74% | ||
| 3 months | -72.10% | ||
| 6 months | -83.21% | ||
| Current year | -78.70% |
1 week
0.07
0.09
1 month
0.070.16
Current year
0.070.61
1 year
0.070.82
3 years
0.0719.87
5 years
0.0719.87
10 years
0.0719.87
| Managers | Title | Age | Since |
|---|---|---|---|
Karin Wehlin
CEO | Chief Executive Officer | - | 02-27 |
Andreas Nyberg
FOU | Founder | 48 | 20-03-18 |
| Director of Finance/CFO | 60 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eva Nilsagård
CHM | Chairman | 60 | 20-12-31 |
| Director/Board Member | 68 | 20-12-31 | |
| Director/Board Member | 39 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.0752 | -5.41% | 710,543 |
| 24-04-25 | 0.0795 | -2.45% | 793,770 |
| 24-04-24 | 0.0815 | -9.34% | 792,550 |
| 24-04-23 | 0.0899 | -2.28% | 207,402 |
| 24-04-22 | 0.092 | +5.26% | 525,756 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:23 am
More quotes
Diagonal Bio AB is a Sweden-based medical research company. The Company is developing a diagnostic platform (Panviral) for detection of any kind of pathogen. Panviralâs technology is based on rapid isothermal amplification of a pathogenâs genome. Multiple tests can be run in parallel, thereby increasing the sample throughput.
Calendar
2024-05-30
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -78.70% | 2.75M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DIABIO Stock
